Easy paper blood test shows brain injury in NMOSD

Credibility

Interest

Share:2 min read

Key Takeaway

A simple, small blood sample dried on paper can reliably measure a brain injury protein (GFAP) that helps tell neuromyelitis optica (NMOSD) apart from MS and relates to disability, opening the door to easier, remote testing.

What They Found

The researchers tested a protein called GFAP (glial fibrillary acidic protein) that rises when certain brain cells called astrocytes are damaged; they compared regular blood tests to dried plasma spots (DPS), which are tiny drops of blood dried on a card. GFAP measured from dried plasma spots matched well with GFAP measured from regular plasma and serum, meaning the smaller, easier sample gave similar results. People with AQP4-IgG NMOSD, a condition that often damages astrocytes, had higher GFAP than people with MS, another condition, and healthy volunteers. Higher GFAP levels were linked to worse disability scores, so the amount of GFAP reflects how much the disease has affected someone. The method used (NULISA) worked well on frozen samples and suggests DPS could be used in future remote or home-friendly testing programs.

Who Should Care and Why

People with MS and their caregivers should care because this test helps tell NMOSD (which can look like MS) apart from MS, and correct diagnosis changes treatment choices — like knowing whether a different medication is needed. Clinicians and neurologists can use GFAP testing to better understand whether symptoms come from astrocyte damage, which is more common in NMOSD than in MS. Patients who live far from clinics or have trouble traveling may benefit if DPS testing is developed for home sampling, similar to a finger-prick test used for diabetes. Caregivers could use this information to push for the right tests when symptoms change, helping avoid delays in getting the correct treatment. Overall, clearer diagnosis and easier testing could lead to quicker, more appropriate care and less stressful clinic visits.

Important Considerations

This study used samples from one center with a small number of people, so the results need checking in larger and more varied groups before this becomes routine. Samples were taken when patients were in remission (not having an attack), so we don’t yet know how well DPS GFAP tracks changes during relapses. Also, while dried plasma spots look promising for remote testing, the study didn’t actually test home self-sampling, so more work is needed to make sure people can do it reliably at home.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Early Research Specific Symptoms

Article Topics:

Neuromyelitis optica spectrum disorder (NMOSD)clinical neuroimmunologydried blood spot samplingfluid biomarkersglial fibrillary acidic protein (GFAP)

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Annals of clinical and translational neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News